Real-world effectiveness of systemic anticancer therapy for advanced melanoma in the west of Scotland from 2010 to 2018
Aim: Assess the real-world effectiveness of systemic anticancer therapy in advanced (unresectable or metastatic) melanoma. Methods: This was a retrospective cohort study linking routine healthcare data with systemic anticancer therapy prescriptions for patients starting immunotherapy or targeted treatments between 1 November 2010 and 31 December 2017 in the west of Scotland. Results: Among 362 patients identified, median overall survival varied between 18.5 months (95% CI: 14.4-not estimable) for ipilimumab/nivolumab combination and 5.6 months (95% CI: 4.5-7.3) for dabrafenib, but there were differences in the characteristics of each regimen cohort. Raised lactate dehydrogenase levels and Eastern Cooperative Oncology Group performance status ≥2 negatively impacted overall survival. Conclusion: The patients had a shorter median overall survival than those in pivotal trials. This was expected, given that this real-world cohort included patients with poorer prognostic indicators, typically excluded from trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Future oncology (London, England) - 19(2023), 6 vom: 02. Feb., Seite 451-461 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Clarke, Julie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Immunotherapy |
|---|
| Anmerkungen: |
Date Completed 10.10.2023 Date Revised 10.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/fon-2022-0959 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355435195 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355435195 | ||
| 003 | DE-627 | ||
| 005 | 20231226064335.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/fon-2022-0959 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355435195 | ||
| 035 | |a (NLM)37039001 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Clarke, Julie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-world effectiveness of systemic anticancer therapy for advanced melanoma in the west of Scotland from 2010 to 2018 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.10.2023 | ||
| 500 | |a Date Revised 10.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: Assess the real-world effectiveness of systemic anticancer therapy in advanced (unresectable or metastatic) melanoma. Methods: This was a retrospective cohort study linking routine healthcare data with systemic anticancer therapy prescriptions for patients starting immunotherapy or targeted treatments between 1 November 2010 and 31 December 2017 in the west of Scotland. Results: Among 362 patients identified, median overall survival varied between 18.5 months (95% CI: 14.4-not estimable) for ipilimumab/nivolumab combination and 5.6 months (95% CI: 4.5-7.3) for dabrafenib, but there were differences in the characteristics of each regimen cohort. Raised lactate dehydrogenase levels and Eastern Cooperative Oncology Group performance status ≥2 negatively impacted overall survival. Conclusion: The patients had a shorter median overall survival than those in pivotal trials. This was expected, given that this real-world cohort included patients with poorer prognostic indicators, typically excluded from trials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a metastatic melanoma | |
| 650 | 4 | |a real-world evidence | |
| 650 | 4 | |a routine clinical practice | |
| 650 | 4 | |a targeted therapy | |
| 650 | 7 | |a Ipilimumab |2 NLM | |
| 700 | 1 | |a Bennie, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Kurdi, Amanj |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Jiafeng |e verfasserin |4 aut | |
| 700 | 1 | |a Mueller, Tanja |e verfasserin |4 aut | |
| 700 | 1 | |a Crearie, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Baillie, Kelly |e verfasserin |4 aut | |
| 700 | 1 | |a Laskey, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Waterston, Ashita |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future oncology (London, England) |d 2005 |g 19(2023), 6 vom: 02. Feb., Seite 451-461 |w (DE-627)NLM161450725 |x 1744-8301 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:6 |g day:02 |g month:02 |g pages:451-461 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/fon-2022-0959 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 6 |b 02 |c 02 |h 451-461 | ||